SOURCE: Market Pulse

March 23, 2005 08:15 ET

Market Pulse Breaking News Alert for Wednesday, March 23, 2005: PKTX: ProtoKinetix's Positive Results Show Synthetic AFGP Preservation of Red Blood Cells!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- March 23, 2005 -- Market Pulse News Alert for this AM, Stocks to Watch are: ProtoKinetix, Inc. (OTC BB: PKTX), Electronic Arts, Inc. (NASDAQ: ERTS), Microsoft Corp. (NASDAQ: MSFT), and Apple Computer Inc. (NASDAQ: AAPL).

Investors need to be watching ProtoKinetix, Inc. (OTC BB: PKTX) this AM! ProtoKinetix is a therapeutic development company whose mission is to develop effective biological therapeutics for the treatment of malignancies. The company is focused on a new generation of monoclonal antibodies termed "Super-antibodies." The company's synthetic Anti-Freeze Glyco Proteins (AFGPs) are in the process of being patented worldwide in a series of intellectual property applications. ProtoKinetix is well o n its way to establishing itself as a significant player in the field of molecular biology for the treatment of cancer! PKTX just had excellent news out before today's opening bell regarding positive results show synthetic AFGP preservation of Red Blood Cells! This could be great news for investors!

Third-party evaluations of ProtoKinetix, Inc.'s (OTC BB: PKTX) proprietary synthesized Antifreeze Glycoproteins (AFGP's) confirm protection for human Red Blood Cell Hemolysis at temperatures down to -15C (minus fifteen degrees Celsius). The Rate of hemolysis (destruction of red blood cells) was dramatically reduced with the presence of the AFGP molecule. ProteoCell Biotechnologies laboratory has shown that red blood cells, in a solution of synthetic AFGP, were preserved in an intact state. Ninety-eight percent (98%) of red blood cells were intact after being subjected to a temperature of -15C (minus fifteen degrees Celsius) for 9 hours in a solution of synthetic AFGP. The red blood cells that were not protected by the synthetic AFGP were all destroyed when exposed to this temperature.

Research conducted over the last 50-years has shown that natural AFGP's found in extreme climate fish, insects, plants and reptiles can preserve cells, tissues and organs at sub-zero temperatures. All of ProtoKinetix experimentation to date proves that the synthetic AFGP, developed by Dr. Jean-Charles Quirion functions in the same way as does the naturally occurring AFGP. ProtoKinetix President Dr. John Todd explains: "The proven stability and non-toxicity of this molecule in addition to the ability to preserve cells is very encouraging." Although testing will be ongoing with the preservation of various cells, tissues and organs, ProtoKinetix now feels that it is in a position to commence commercial exploitation.

ProtoKinetix President and CEO, Dr. John Todd, has been interviewed by AudioStocks regarding this new release and an AudioNews™ file will be available to be listened to beginning at 8 am PST. Please visit http://www.audiostocks.com in order to hear the interview.

About ProtoKinetix

ProtoKinetix, Inc. is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial market place will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development.

Stocks that closed down in yesterday's trading include: Electronic Arts, Inc. (NASDAQ: ERTS), Microsoft Corp. (NASDAQ: MSFT), and Apple Computer Inc. (NASDAQ: AAPL).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated in free trading shares of common stock, available for public trading as follows: ProtoKinetix, Inc. compensation from a third party shareholder: two hundred thousand free trading shares of stock in ProtoKinetix, Inc., already delivered from a third party shareholder. To date, MP has sold one hundred thousand shares of stock in ProtoKinetix, Inc. for proceeds totaling seventy five thousand seven hundred dollars. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market Pulse News Alert is a division of MP.

Contact Information